AIBNs Delivery of Drugs and Genes Group (D2G2) lead by Professor Mark Kendall focuses on physical methods for delivering biomolecules and stimuli to key immune response-inducing cells located in the skin; and extracting important biomolecules for diagnostics purposes.
The ultimate goal of the research is to dramatically improve the cost and efficiency of vaccination and treatment of major diseases, such as malaria and influenza. To achieve this goal, the group is:
|developing needle-free gene and drug delivery and extraction technologies to and from the skin||
investigating micro-nanoprojection array patch (Nanopatch) technology
measuring the key biological and mechanical properties of skin
|assessing clinical application|
This multidisciplinary research spans biomedical engineering (fluid mechanics; micro-nanofabrication; solid mechanics), diagnostic (multi-photon microscopy) and dermatology and vaccinology.
The D2G2 group has research projects covering:
|micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells||micro-nanoprojection patches for targeted gene and drug delivery to the skin and improved DNA vaccines|
|micro-nanoprojection patches for improved sampling in diagnosis of disease||multi-photon microscopy for in vivo imaging following delivery of drugs and vaccines to skin|
|MPM non-invasive imaging of biological interactions following drug delivery with micro-nanoprojection patches||
measurement of mechanical properties in skin at the cellular and subcellular scale
|developing medical devices for clinical use|